The takeover of Corporate Venture Capital – how CVCs passed traditional VC volume in the US in 2018, how does it compare to Europe and Israel and what are the drivers for this unprecedented level of CVC investment?
Teva Launched Corporate Venture Arm to Invest in Biomed [Guest Post]
Last month, Teva Pharmaceuticals, has announced the launch of a corporate venture capital fund. The new fund will be headed by Dr. Aaron Schwarz, a Teva veteran, and will seek investment in biotech companies. In doing so, Teva joins a list of leading pharmaceuticals that increasingly shift their attention externally as a way to stimulate their product pipeline.
